Search Submit

Journal of Applied Clinical Pathology (JACP)

Martin H. Bluth(Editor-in-Chief)
Online ISSN: 2639-8141

Journal of Applied Clinical Pathology (JACP)

Martin H. Bluth(Editor-in-Chief)

Welcome to the Journal of Applied Clinical Pathology (JACP)! The field of clinical pathology and laboratory medicine is expanding at a remarkable rate with applications to novel biomarkers towards existing as well as new disease spaces, laboratory centric pharmacovigilance, automation, information technology, sensor based technology and the like. Laboratory Medicine’s positioning in patient management with respect to disease diagnosis and prognosis is becoming integral to “pay for performance” initiatives, laboratory utilization and payor logistics. It is the intention of the Journal to become the premier publication for the discipline of clinical pathology and laboratory medicine due to its expert editorial board and peer reviewer base, competitive publication fee schedule, international open access visibility and retention of copyright to you – the author – as a means for you to maintain control and promote increased visibility of your important contributions related to laboratory centric healthcare.

I invite you to submit your groundbreaking seminal works to the Journal including original research, new methods, reviews, editorials, and critical evaluations, case reports and short papers in the field of clinical pathology and laboratory medicine. The Journal focuses on the expanding role of the clinical laboratory and its professionals in the translational, clinical and public healthcare sectors as it relates to the diagnosis and management of human disease.

The scope of the Journal encompasses laboratory-centric human disease diagnosis and management including chemical pathology (i.e. clinical chemistry, endocrinology, hormone assays), clinical toxicology (i.e. drug monitoring), clinical microbiology (i.e. bacteriology, mycology, parasitology and virology), hematology/ hematopathology (i.e. flow cytometry, oncology), immunology/ serology (i.e. infectious disease, autoimmunity), transfusion medicine (i.e. immunohematology, blood utilization), molecular pathology, (i.e. precision medicine, cytogenetics, genomics), laboratory logistics (i.e. management, automation, informatics), applied biotechnology and other related disciplines.

It is our intention to provide the field of clinical pathology a unique vantage point in the global medical publication arena and provide the discipline with the attention it deserves. The ability to highlight clinical pathology – also known as “fluids medicine” – in the continuously changing healthcare landscape will offer a unique perspective and projection of this discipline to provide and affect patient centric, evidenced based, fiscally responsible healthcare as well as influence laboratory centric healthcare policy and patient management. It is my pleasure to welcome you.


Martin H. Bluth, MD, PhD

Editor in Chief

Journal of Applied Clinical Pathology (JACP)

Martin H. Bluth, MD, PhD

Dr. Bluth completed his MD and PhD (Immunology) degrees at SUNY Downstate Medical Center, residency in Clinical Pathology at Kings County Hospital, his fellowship training in Transfusion Medicine at the New York Blood Center and post-doctoral fellowship in tumor markers at the Veteran’s Affairs Medical Center in NY. He maintains board certification in his disciplines. He previously served as Chief Medical Officer for Consolidated Laboratory Management Systems, Vice President for BioMedica Corporation, Director of Research for SUNY Downstate Medical Center among other top tier positions and currently holds an appointment as Professor of Pathology at Wayne State University School of Medicine, Director of Pathology Laboratories for Michigan Surgical Hospital and National Medical Director for Kids Kicking Cancer. He also serves as Associate Editor for Henry’s Clinical Diagnosis and Management by Laboratory Methods, the premier textbook on Clinical Pathology and Laboratory Medicine, as Editor in Chief for four peer reviewed medical journals, and reviews for over a dozen other journals in various disciplines. He is a serial entrepreneur and founder of Bluth Bio Industries, LLC which provides consultation as well as facilitates and matures novel biomarkers, devices and therapeutics ( Dr. Bluth is a leader in laboratory centric drug testing and pharmacovigilance guidance and serves on numerous committees including the Michigan State Medical Society Committee on Health Care Quality, Efficiency and Economics, and consults for numerous healthcare associations and political advocacy entities. Dr. Bluth is considered an expert in his fields, has authored over 250 publications, and is sought after for speaking engagements and consultation worldwide.

Coming Soon...

    Coming Soon...

Editorial Board

  • Kai Cao, MS, MD, D(ABHI)

    Professor, Department of Laboratory Medicine, Division of Pathology/Lab Medicine,
    The University of Texas MD Anderson Cancer Center, Houston, TX
    United States
    Dr. Cao received her medical degree from China Medical University in Shenyang, China, and a master degree in Dermatology. After a one-year scholarship in the Laboratory of Immunogenetics at the National Cancer Research Institute in Genova, Italy, she joined the National Histocompatibility Laboratory of the American Red Cross later the Histocompatibility Laboratory at the University of Maryland Medical System. Then she went to work at the C.W. Bill Young/Department of Defense Marrow Donor Program as Supervisor and Research Instructor at the Georgetown University School of medicine. Right after working at the HLA laboratory of Cedars-Sinai Medical Center (CSMC) in Los Angeles, California entitled Chief PhD and administratively as the Assistant/Associate Director, she was recruited to The University of Texas, MD Anderson Cancer Center as Professor and HLA Laboratory Director. Dr. Kai Cao's research interests are HLA polymorphism identification and differentiation methodologies, HLA gene frequencies in different ethnic groups, HLA haplotype frequencies, population distribution; HLA and diseases association studies; Identification of new HLA genes (alleles), compile and report rare HLA alleles; Killer Immunoglobulin-like Receptor (KIR): polymorphism, typing methodologies, KIR haplotypes, KIR HLA ligand mismatching and their impact on allogeneic hematopoietic stem cell and umbilical cord blood transplantation. Her clinical interests are HLA matching and graft outcome in hematopoietic stem cell and umbilical cord blood unit transplantation; NK cell benefit from selected donors to patients through graft-versus-leukemia effect in hematopoietic stem cell or umbilical cord blood unit transplantation; Impact of anti-HLA antibodies in patients who need related or unrelated allogeneic hematopoietic stem cell transplantation. Anti-HLA antibody monitoring in these patients for guiding patients’ preemptive immune therapeutic treatment, optimal donor selection and monitoring post-transplant.
  • Michael Hogarth, MD, FACP, FACMI

    Director, Section of Pathology Informatics , Department of Pathology and Laboratory Medicine
    University of California Davis Health System
    United States
    Dr. Michael Hogarth is board certified Internal Medicine physician and clinical attending faculty on the Internal Medicine in-patient services at UC Davis Health System. He currently also serves as an informatics and data quality lead for the UC Davis Health System healthcare analytics group. He is also Vice Chair for Informatics in the Department of Pathology where he manages a pathology informatics team supporting a number of grant and contract funded activities. Dr. Hogarth has been the informatics lead for a number of large-scale initiatives. These include California Electronic Death Registration System (California EDRS), the Athena Breast Health Network project , the novel I-SPY2 adaptive breast cancer clinical trial, and the pSCANNER clinical data research network (CDRN). He is also the UC Davis principal investigator for the California Precision Medicine Consortium (CaPMC), which was recently awarded a grant to recruit patients into the NIH funded national precision medicine registry. In 2015 he was elected to the American College of Medical Informatics (ACMI). He is also a founding volunteer advisor for Health Technology Forum, an organization of over 10,000 participants who attend monthly gatherings in 16 cities across 3 continents to promote the development of innovative technologies to transform medicine and improve access to care.
  • Ashok Kumar Mukhopadhyay, MBBS, MD

    Professor & Head, Department of Laboratory Medicine
    All India Institute of Medical Sciences
    India (भारत)

    Dr. A. K. Mukhopadhyay received his medical degree (MBBS) from the University of the Calcutta in 1977 and got his postgraduate medical degree  (MD) in Pathology in 1981 following three-year residency from All India Institute of Medical science (AIIMS).  Since then he is at AIIMS holding various positions.  He is Professor of the Dept of Laboratory Medicine at this India’s premier Institute for last 15 years and Head of the Dept. for last 11 years. He is the pioneer in India to start the MD course in Laboratory Medicine, which has been running since 1997. Routinely he supervises about one million investigations, per annum, of the outpatients and inpatients of AIIMS.  He built up carrier of several students in Laboratory Medicine awarding them MD or PhD degree. He is examiner in Pathology for several eminent universities in India. His research interest is in neurodegenerative disease, molecular psychiatry, psychobiology and biologically inspired systems science.

  • Meghan May

    Department of Biomedical Sciences
    University of New England
    United States

    Dr. May received her doctoral degree in pathology and veterinary science (bacteriology track) from the University of Connecticut. She is an associate professor of microbiology and infectious disease at the University of New England College of Osteopathic Medicine. She was previously appointed in the Department of Biological Sciences at Towson University (holding the Fisher Endowed Chair of Biological Sciences from 2012-2013) and was appointed as a postdoctoral fellow and then a research assistant professor in the Department of Infectious Diseases and Pathology at the University of Florida's Emerging Pathogens Institute. Her research topics include the evolution of virulence in bacterial (Mycoplasma), parasitic (Filariae), and viral (Zika Virus) systems; infection-mediated pain; and investigates novel diagnostic tests for antimicrobial resistance and Lyme disease. Dr. May has been funded by the National Institutes of Health, is a past chair of the American Society for Microbiology’s Division G, chair of the International Research Programme in Comparative Mycoplasmology’s Molecular Genetics Team, and an elected member of the International Committee for the Systematics of Prokaryotes (Mollicutes Taxonomy Subcommittee). She also volunteers professional time for ASM’s international laboratory capacity (LabCAP) program and for the United Nations Educational, Scientific, and Cultural Organization. She is the author of 31 peer-reviewed publications and 8 invited book chapters, and has given several platform presentations at national and international meetings.

  • Adil I. Khan, MSc, PhD

    Director, Clinical Chemistry; Assistant Professor, Department of Pathology
    Temple University
    United States
    Dr. Adil Khan is the Director of Point of Care Testing at Temple University and Episcopal Hospitals and Director of the Chemical Pathology Laboratories at Temple University and Episcopal Hospitals and Northeastern Ambulatory Care Center, Philadelphia, Pennsylvania, USA. He also holds an academic appointment at Temple University Lewis Katz School of Medicine as an Assistant Professor of Pathology. His research interests include understanding the role of adhesion molecules in leukocyte recruitment in health and disease; identifying novel markers of inflammation; clinical trials of point of care testing devices and clinical laboratory instruments. In addition to this he also has served as the Chair for the Philadelphia Section of the American Association for Clinical Chemistry and is an elected representative for United States in the International Federation of Clinical Chemistry and Laboratory Medicine Task Force on Point of Care Testing. He has been the recipient of the American Association for Clinical Chemistry Recognition Award in 2007, 2008, 2009, 2010, 2012 and 2013.
  • Geralyn Lambert-Messerlian, MD, PhD, FACB

    Professor, Department of Pathology and Laboratory Medicine
    Brown University
    United States
    Dr. Lambert-Messerlian received her doctoral degree in Biology from Boston University. She completed a fellowship in Reproductive Endocrinology at the Massachusetts General Hospital, Harvard University.
  • Li Juan Wang, MD, PhD

    Associate Professor, Department of Pathology
    Brown University
    United States
    Dr. Wang is an Associate Professor of Pathology and Laboratory Medicine at the Warren Alpert School of Medicine at Brown University. She received her MD from Beijing University School of Medicine (Peking University Health Science Center), Beijing, China, and her PhD from the University of Louisville in Louisville KY. She is board-certified in anatomic pathology and clinical pathology by the American Board of Pathology, and has been in practice for more than 15 years. She has special interests in gastrointestinal and genitourinary pathology and the application of immunohistochemical and molecular classifications in surgical pathology to optimize clinical outcomes. Over the years, she served as Pathology Residency Director at the Warren Alpert School of Medicine at Brown University, Chief of Service of Pathology Department at Roger Williams Medical Center (RWMC), and Gastrointestinal Pathology Fellowship Director at RWMC. Currently she is the Medical director of pathology at The Miriam Hospital. She is an editorial board member of Journal of Clinical and Laboratory Medicine, and authored or coauthored numerous peer-reviewed publications. She has been extensively involved in medical student and residency education.
  • Xu Zeng, MD, PhD

    Associate Professor, Department of Pathology, Immunology and Laboratory Medicine
    University of Florida
    United States
    Dr. Xu Zeng, is board-certified in anatomic/clinical pathology. He graduated from Guangzhou Medical College, China for his MD and Medical College of Ohio, USA for his PhD in medical science with honor. Dr. Zeng completed an anatomic and clinical pathology residency at Long Island Jewish Medical Center in the New Hyde Park, New York. He later completed a Renal Pathology Fellowship at Johns Hopkins Medical Institute, Baltimore Maryland. After working in Wayne State University, Bostwick Laboratory and Temple University for a number of years, Dr. Zeng joined the faculty of the University of Florida Department of Pathology, Immunology and Laboratory Medicine as a renal pathologist. His interests include studying mechanism of proliferative glomerulonephritis, including lupus nephritis.
  • Carrie Schneider, MD

    Assistant Professor, Department of Pathology and Laboratory Medicine
    Temple University
    United States

    Dr. Schneider is currently an Assistant Professor at the Lewis Katz School of Medicine at Temple University. She received her MD from the Drexel University College of Medicine followed by an anatomic and clinical pathology residency at Temple University and a surgical pathology fellowship at the Hospital of the University of Pennsylvania. She is board certified in anatomic and clinical pathology by the American Board of Pathology.  She is a practicing surgical pathologist with areas of interest in dermatopathology and gastrointestinal pathology. Dr. Schneider also has a strong interest in medical education and serves as the Director of the pathology residency program at Temple University Hospital.

  • Jieliang Li, PhD

    Department of Pathology and Laboratory Medicine
    Temple University
    United States
    Dr. Li received his PhD degree in Biochemistry & Molecular Pharmacology from the College of Science and Engineering, City University of Hong Kong, Hong Kong in 2007. He then joined the Department of Pharmacology at the University of Pennsylvania as a postdoctoral fellow, engaging in the liver inflammation and hepatocellular carcinogenesis research. In 2009, Dr. Li moved to the Department of Pathology and Laboratory Medicine at Temple University and studied the blood-brain barrier (BBB) and HIV neuroinvasion. The BBB is a dynamic interface that separates the brain from the circulatory system and protects the CNS from potentially pathogens or harmful chemicals. The active role of BBB in viral sensing and innate immunity at the CNS vasculature has recently been acknowledged. Dr. Li’s research showed that brain microvascular endothelial cells (BMVEC) express functional TLR3/RIG-I, the activation of which induced the expression of antiviral IFN-β and IFN-λ [Li et al. Blood 2013]. IFN- λ was latter reported with a new function in tightening the BBB by modulating tight junctions, thus restricting pathogen entry into the brain parenchyma. Dr. Li recently reported that exosomes released from TLR3-activated BMVEC confer to the antiviral response [Sun et al. Antiviral Res 2016]. Parallelly, exosomes isolated from plasma of HIV-infected subjects contained very significantly higher levels of miR-17 and miR-20a that can target tight junction proteins. Some other increased miRNAs (let-7 family, miR-21) have been reported with neurotoxic impact. Dr. Li is now further investigating the impact of plasma exosomes on the BBB integrity, the activation and transendothelial migration of circulating monocytes, as well as on the neuronal survival. Dr. Li’s laboratory is utilizing a set of multifunctional experimental paradigms to dissect the role of plasma exosomes and exosomal miRNA cargos on BBB functions, CNS homeostasis and neurotoxicity.
  • Ziyan Salih, MD. FIAC

    Department of Pathology
    Wake Forest University
    United States

    Dr. Ziyan Salih received her medical degree from the University of the Salahaddin, School of Medicine. She completed her anatomic and clinical pathology residency training at the University of Mississippi Medical Center, Jackson, MS, and her Fellowship training in surgical pathology and cytopathology at Emory University Hospital, Atlanta, GA. She currently practices surgical pathology and cytopathology at Wake Forest Baptist Medical Center, Winston-Salem, NC. Dr. is board certified in Anatomic Pathology, Clinical Pathology and Cytopathology by the American Board of Pathology and is board certified by the International Board of Cytopathology by the International Academy of Cytopathology. Dr. Salih’s interests include breast pathology, cytopathology, circulating tumor cells and malignancies of unknown origin.

Assistant Editors

    Coming Soon...

Early View

  • Platelet-Rich Plasma in Treatment of Plantar Fasciitis: Randomized Double-Blinded Placebo Controlled Study

    The use of PRP injection for treatment of plantar fasciitis resulted in significant improvement in pain according to VAS, PRS, and FFI and a reduction in the thickness of the plantar fascia as measured by US, compared to the saline group.

    Journal of Applied Clinical Pathology. 2019;2(1):1
    DOI: 10.24983/scitemed.jacp.2019.00097
    Article Type: Original Article

Current Issue

Volume 1, Issue 1

  • Clinical Laboratory Medicine as the Emerging Healthcare Partner

    The clinical pathologist/laboratory medicine physician serves as the ideal health care partner to synergize with the patient-physician-unit to temper curious results, obviate the “light switch” effect, provide guidance on current and emerging test utilization and management, navigate the DTC marketplace and educate patient and physician alike as required, and to ultimately incorporate lab test results into actual optimization of patient care. It is through this approach that the patient-physician-laboratorian triumvirate can maximize the experience to positively affect patient centric, evidenced based, fiscally responsible healthcare in the ever-changing medical landscape.

    Journal of Applied Clinical Pathology. 2017;1(1):1
    DOI: 10.24983/scitemed.jacp.2017.00031
    Article Type: Editorial
  • Medical Laboratory Disciplines: Time for Academic Reform and Structural Organization

    Journal of Applied Clinical Pathology. 2017;1(1):2
    DOI: 10.24983/scitemed.jacp.2017.00032
    Article Type: Editorial
  • Brain Metastasis of Breast Cancer: Crossing the Blood-brain Barrier

    The high incidence of brain metastasis and the comparison of metastatic and non-metastatic phenotypes indicate an active crosstalk of brain metastatic breast cancers with the BBB. Certain miRNAs and serpins are regulatory molecules in defining the metastatic potential of breast cancers. Targeting these factors that favor the metastatic microenvironment may provide future therapeutic interventions for the brain metastasis of breast cancers.

    Journal of Applied Clinical Pathology. 2017;1(1):3
    DOI: 10.24983/scitemed.jacp.2017.00043
    Article Type: Review Article
  • Can Whole Slide Imaging Replace Conventional Microscopic Evaluation? A Comparative Study over a Spectrum of Cases

    This pilot study compares the agreement in diagnosis between scanned slides and conventional microscopy in both low and high magnifications.

    Journal of Applied Clinical Pathology. 2018;1(1):4
    DOI: 10.24983/scitemed.jacp.2018.00060
    Article Type: Original Article
  • Detection of Malignancy in Body Fluids: A Comparison of the Hematology and Cytology Laboratories

    An increasing burden is loaded on clinical laboratories for daily testing of body fluids, including pleural fluid, peritoneal fluid (ascites), pericardial fluid, and cerebrospinal fluid. The request for detection of cellular components in the body fluid samples is usually delivered simultaneously to the hospital’s hematology laboratory and cytology laboratory. The medical technologists of hematology laboratory provide the screening result for suspicious malignant cells; meanwhile, the pathologists of cytology laboratory provide the presence of cancer cells at a diagnostic level. However, unfortunately, neither of these results reaches 100% sensitivity or specificity. To assess the clinical practice values, the present study performed a comparison of the hematology and cytology laboratories on the detection of malignancy in body fluids.

    Journal of Applied Clinical Pathology. 2018;1(1):5
    DOI: 10.24983/scitemed.jacp.2018.00077
    Article Type: Original Article